Contrive Datum Insights has published "Microbiome Therapeutics Market Size, Share & Industry Analysis, By Product type (Live Biotherapeutic Products (LBPs), Fecal Microbiota Products, Microbiome-Derived Small Molecules and Metabolites, Prebiotic-Based Therapeutics, Bacteriophage Therapeutics, Microbiome-Targeted Biologics and Antimicrobials), Indication (Clostridioides difficile Infection, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Metabolic Disorders, Oncology and Immuno-Oncology, Dermatological Conditions, Neurological and CNS Disorders, Vaginal and Urogenital Infections, Other Indications), Route of administration (Oral, Rectal, Topical, Vaginal, Nasogastric/Nasoduodenal), Source of microbiota (Human Donor-Derived, Cultured Isolate-Derived, Synthetically Engineered, Food-Derived), Development stage (Approved and Marketed, Phase III, Phase II, Phase I, Preclinical), Therapeutic area (Gastroenterology, Infectious Diseases, Metabolic and Endocrine, Oncology, Dermatology, Neurology, Women's Health), Dosage form (Capsules, Liquid Suspensions, Powders, Topical Formulations, Tablets), Patient age group (Adults, Geriatric, Paediatric), Regulatory pathway (Biologic (BLA/Drug) Pathway, Medicinal Product (EMA/MAA) Pathway, Enforcement Discretion/Special Access, Hospital Exemption), End user (Hospitals, Specialty Clinics, Ambulatory Care Centers, Homecare Settings), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies), and Regional Forecast, 2026-2034". The study sizes the global microbiome therapeutics market at USD 260 million in 2025 and projects growth from USD 335 million in 2026 to USD 1690 million by 2034, a compound annual growth rate of 22.42% across the forecast period.
Microbiome therapeutics are medicines that treat or prevent disease by delivering, modifying or targeting the microorganisms that live in and on the body. The category covers live biotherapeutic products, fecal microbiota preparations, bacteriophages, microbiome-derived metabolites and small molecules, prebiotic-based therapeutics and biologics aimed at the microbiome, supplied as capsules, suspensions, powders, tablets and topical forms. Buyers are hospitals, specialty clinics, ambulatory centres and patients treated at home, supplied through hospital, retail, specialty and online pharmacies.
Uptake of approved oral live biotherapeutics in recurrent infection
Uptake of approved oral live biotherapeutics in recurrent infection is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 22.42% a year, the product type lines exposed to it move fastest: Bacteriophage Therapeutics compounds at 31.5%, taking its share of revenue from 4% to 8% and its value from USD 10.4 million to USD 135.2 million.
The study also runs a bull case: late-stage programmes in inflammatory bowel, metabolic and oncology indications read out positively on schedule, payers extend coverage of oral products beyond recurrent infection, and manufacturing scale lowers the cost per course faster than planned. That path ends 2034 at USD 2146.3 million, above the USD 1690 million base case.
Against that, several late-stage programmes fail or are delayed, reimbursement stays restricted to recurrent infection, and quality or supply problems at contract manufacturers slow the launch of new products. On that reading 2034 revenue stops at USD 1233.7 million. The weight of the problem sits in Fecal Microbiota Products: 30% of 2025 revenue growing at 15%, well under the market's 22.42%.
The Competitive Split Runs by Product type
Competition in the global microbiome therapeutics market runs along the product type axis, not the regional one. Live Biotherapeutic Products (LBPs) holds 38% of 2025 revenue at USD 98.8 million and remains the largest line through 2034 at 40%, making it the position hardest for a challenger to take. Bacteriophage Therapeutics, growing at 31.5%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 260 million.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Indication | Clostridioides difficile Infection | 52% · USD 135.2 million | Oncology and Immuno-Oncology 40.7% |
| Route of administration | Oral | 56% · USD 145.6 million | Topical 26.6% |
| Source of microbiota | Cultured Isolate-Derived | 44% · USD 114.4 million | Synthetically Engineered 42.6% |
| Development stage | Approved and Marketed | 78% · USD 202.8 million | — |
| Therapeutic area | Infectious Diseases | 44% · USD 114.4 million | Oncology 40.7% |
| Dosage form | Capsules | 52% · USD 135.2 million | Tablets 43.6% |
| Patient age group | Adults | 82% · USD 213.2 million | Geriatric 30.7% |
| Regulatory pathway | Biologic (BLA/Drug) Pathway | 55% · USD 143 million | Medicinal Product (EMA/MAA) Pathway 27.8% |
| End user | Hospitals | 58% · USD 150.8 million | Ambulatory Care Centers 28.8% |
| Distribution channel | Hospital Pharmacies | 46% · USD 119.6 million | Online Pharmacies 33% |
- Regionally, the lead sits with North America: 53% of 2025 global revenue, USD 137.8 million rising to USD 743.6 million in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 15% in 2025 to 24% in 2034, with revenue growing from USD 39 million to USD 405.6 million.
- Latin America stays the smallest contributor across the period: 3% of revenue in 2025 and 3% in 2034.
- Live Biotherapeutic Products (LBPs) was the leading product type line in 2025, taking 38% of revenue at USD 98.8 million.
- The fastest product type line is Bacteriophage Therapeutics, forecast to compound at 31.5% through the period.
- The United States is the largest single country market at USD 128 million in 2025, 49.23% of global revenue.
Coverage runs to eleven axes, by product type, and by indication, route of administration, source of microbiota, development stage, therapeutic area, dosage form, patient age group, regulatory pathway, end user and distribution channel, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 1233.7 million and USD 2146.3 million by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.